[1]张永州,娄婷婷,李利平.越婢加半夏汤治疗细菌性肺炎疗效及对患者免疫水平的影响[J].陕西中医,2022,(2):185-188.[doi:DOI:10.3969/j.issn.1000-7369.2022.02.010]
　ZHANG Yongzhou,LOU Tingting,LI Liping.Effect of Yuebijia Banxia decoction on bacterial pneumonia and its influence on patients' immune levels[J].,2022,(2):185-188.[doi:DOI:10.3969/j.issn.1000-7369.2022.02.010]
点击复制

越婢加半夏汤治疗细菌性肺炎疗效及对患者免疫水平的影响
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2022年2期
页码:
185-188
栏目:
临床研究
出版日期:
2022-02-05

文章信息/Info

Title:
Effect of Yuebijia Banxia decoction on bacterial pneumonia and its influence on patients' immune levels
作者:
张永州1; 娄婷婷1; 李利平2
(1.河南大学淮河医院,河南 开封 475000; 2.郑州大学第三附属医院,河南 郑州 450014)
Author(s):
ZHANG Yongzhou; LOU Tingting; LI Liping
(Huaihe Hospital of Henan University,Kaifeng 475000,China )
关键词:
细菌性肺炎;  越婢加半夏汤;  中医证候积分;  免疫球蛋白;  炎性指标
Keywords:
Bacterial pneumonia;  Yuebijia Banxia decoction;  TCM syndrome score;  Immunoglobulin;  Inflammatory indicators
分类号:
R 563.1
DOI:
DOI:10.3969/j.issn.1000-7369.2022.02.010
文献标志码:
A
摘要:
目的:探究越婢加半夏汤辅助西药治疗细菌性肺炎的临床疗效。方法:选择91例细菌感染肺炎患者作为研究对象,以电脑随机数法将其分为试验组和对照组,其中对照组45例给予莫沙西星治疗,试验组46例给予莫西沙星联合越婢加半夏汤治疗,比较两组患者给药2周后的临床疗效、中医症候积分、免疫细胞[免疫球蛋白(IgA、IgM)]及炎性指标[白细胞计数(WBC)]、不良反应发生率。结果:试验组临床疗效优于对照组(P<0.05); 治疗后,两组各项中医症候积分均低于治疗前,且试验组均低于对照组(P<0.05); 两组治疗后的IgA、IgM水平均高于治疗前,试验组高于对照组(P<0.05); 两组治疗后的WBC水平均低于治疗前,试验组低于对照组(P<0.05); 对照组体温恢复时间、肺部啰音及咳嗽消失时间均长于试验组(P<0.05); 两组患者治疗期间不良反应发生率比较,差异无统计学意义(P>0.05)。结论:越婢加半夏汤辅助西药治疗细菌性肺炎,可有效缩短患者临床症状恢复时间,调节免疫指标水平,临床疗效较好且未明显增加不良反应发生率。
Abstract:
Objective:To explore the clinical efficacy of Yuebijia Banxia decoction in the treatment of bacterial pneumonia Methods:The 91 patients with bacterial infection and pneumonia were selected as the research objects,and they were divided into the experimental group and the control group by computer random number method,45 cases of the control group were treated with moxacin.46 patients in experimental group were treated with moxacilcin combined with Yuebijia Banxia decoction,and the clinical efficacy,TCM syndrome score,immune cells [immunoglobulin(IgA,IgM)] and inflammatory indicators(WBC).incidence of adverse reactions of the two groups after 2 weeks of administration were compared.Results:The clinical efficacy of the experimental group was better than that of the control group(P<0.05),after treatment,the scores of various TCM syndromes in the two groups were lower than before treatment,and the experimental group was lower than the control group(P<0.05).The levels of IgA and IgM after treatment in the 2 groups were higher than those before treatment,and the experimental group was higher than the control group(P<0.05).WBC levels after treatment in the 2 groups were lower than before treatment,and the experimental group was lower than the control group(P<0.05),the control group's body temperature recovery time,lung rales and cough disappearance time were longer than those of the experimental group(P<0.05),there was no significant difference in the incidence of adverse reactions between the two groups during treatment(P>0.05).Conclusion:Yuebijia Banxia decoction assisted western medicine in the treatment of bacterial pneumonia,which can effectively shorten the recovery time of patients' clinical symptoms,adjust the level of immune indicators,and have good clinical effects without significantly increasing the incidence of adverse reactions.

参考文献/References:

[1] 王 燕,华 英,徐伟杰,等.双苓清肺汤联合参麦注射液治疗老年细菌感染性肺炎的临床观察[J].中国中医药科技,2019,26(3):376-378.
[2] 黄小玉,梁爱武,杨红梅,等.清肺通腑汤灌肠辅助治疗对医院获得性肺炎肺热腑实证血清炎症因子及肺部CT积分的影响[J].山西中医,2020,36(9):16-19.
[3] Liapikou A,Cilloniz C,Palomeque A,et al.Emerging antibiotics for community-acquired pneumonia[J].Expert Opin Emerg Drugs,2019,24(4):221-231.
[4] Stets R,Popescu M,Gonong JR,et al.Omadacycline for community-acquired bacterial pneumonia[J].N Engl J Med,2019,380(6):517-527.
[5] Sharma R,Sandrock CE,Meehan J,et al.Community-acquired bacterial pneumonia-changing epidemiology,resistance patterns,and newer antibiotics:Spotlight on delafloxacin [J].Clin Drug Investig,2020,40(10):947-960.
[6] 王维亮,林杏华.清气化痰汤治疗社区获得性肺炎(痰热壅肺证)的疗效观察[J].中国中医急症,2020,29(2):338-340.
[7] 郑 艳.泻肺化痰汤联合西药治疗痰热壅肺型社区获得性肺炎85例[J].中国中医药科技,2020,27(3):405-407.
[8] 李 岩,施 芳.越婢加半夏汤化裁辨治风寒外束痰热内蕴证慢性支气管炎临床研究[J].新中医,2019,51(5):56-60.
[9] 倪 伟.内科学[M].9版.北京:中国中医药出版社,2012:45-48.
[10] 中华医学会呼吸病学分会.中国成人社区获得性肺炎诊断和治疗指南(2016年版)[J].中华结核和呼吸杂志,2016,39(4):253-279.
[11] 张 泳,曾博煌,龚玉明.直接药敏试验在细菌性肺炎患者中的应用价值[J].山西医药杂志,2020,49(14):1793-1795.
[12] 姚明慧,曹燕秋,王 妍,等.越婢加半夏汤加味辅助治疗重症肺炎痰热壅肺证临床研究[J].国际中医中药杂志,2020,42(12):1112-1116.
[13] 贾 维,刘 杨,房 建,等.痰热清注射液联合阿奇霉素治疗社区获得性肺炎的临床疗效[J].山西医药杂志,2019,48(8):913-915.
[14] Postma DF,Spitoni C,Werkhoven CH,et al.Cardiac events after macrolides or fluoroquinolones in patients hospitalized for community-acquired pneumonia:Post-hoc analysis of a cluster-randomized trial [J].BMC Infect Dis,2019,19(1):17.
[15] Mccurdy S,Nenninger A,Sheets A,et al.Efficacy of delafloxacin versus moxifloxacin against atypical bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia(CABP):Data from the delafloxacin phase 3 CABP trial [J].Int J Infect Dis,2020(97):374-379.
[16] 李官洪,孙晓静,邓银河,等.清金化痰汤治疗老年社区获得性肺炎的Meta分析及试验序贯分析[J].中国中药杂志,2020,45(11):2658-2667.
[17] 李志尚,蔡海荣,张为章,等.宣白承气汤加味治疗老年社区获得性肺炎的临床研究[J].中国中医急症,2019,28(6):965-968.
[18] 倪海滨,马 达,朱 瑾,等.清金化痰汤联合抗生素治疗细菌性社区获得性肺炎的疗效[J].江苏医药,2019,45(7):730-732.
[19] 狄冠麟,朱振刚,郑延龙.越婢加半夏汤对老年社区获得性肺炎痰热壅肺证及对炎性标志物预后的影响[J].中国实验方剂学杂志,2020,26(22):59-64.
[20] Vadamalai K,Sanche TD,Bress J,et al.Screening for humoral immunodeficiency in patients with community-acquired pneumonia [J].J Hosp Med,2019,14(1):33037.
[21] 任佳羽,杨贵方,胡松岩,等.越婢加半夏汤降低过敏性哮喘小鼠的血清IgE和升高肺组织中SOD的活力[J].中国比较医学杂志,2015,21(9):18-21.

备注/Memo

备注/Memo:
基金项目:河南省医学科技攻关项目(201304023)
更新日期/Last Update: 2022-02-09